The stock price of Samsung Biologics, which has signed the largest contract since its establishment, is on the rise.
As of 9:34 a.m. on the 14th, Samsung Biologics is trading at 1.03 million won, a 1.78% increase from the previous day.
On that day, Samsung Biologics announced it had signed a massive contract for contract manufacturing organization (CMO) services valued at $1.41011 billion (approximately 2.8 trillion won) with a pharmaceutical company based in Europe.
This scale is the largest ever since its founding and represents about 40% of last year's total order amount of 5.4035 trillion won. The contract period extends until Dec. 31, 2030, and due to confidentiality agreements, the counterparty and product names were not disclosed.
Samsung Biologics secured a large-scale order just over three months after signing a contract worth 1.7028 trillion won with a pharmaceutical company in Asia last October.
Moreover, a research institute at Korea Investment & Securities noted that "Samsung Biologics will record sales of 5.362 trillion won and operating profit of 1.614 trillion won due to revenue growth from ramping up the fourth factory this year," adding that "the revenue from the fifth factory, which will operate from April, will be recognized from the second quarter of next year, but the ongoing orders throughout the year will raise expectations for medium- to long-term sales."
Meanwhile, Samsung Biologics plans to attend the "2025 JP Morgan Healthcare Conference" (JPM) in San Francisco, U.S., from the 13th to the 16th (local time) to announce its business plans and medium- to long-term vision for this year.